Want to join the conversation?
$REGN will be starting a 10,000 patient long-term treatment phase 3 clinical study of Fasinumab in 1H16. The company anticipates reporting data from a 16-week study in osteoarthritis pain in 1H16. In the early-stage pipeline, $REGN will share data from phase 1 and 2 studies of Evinacumab, antibody ANGPTL3 for dyslipidemia in 1H16.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.